Hepatitis C Research

Page Three

2002 HCV Related Plenary Highlights from DDW

(back to :2001 Highlights from DDW)

BACK TO: Reports from Digestive Disease Week 2003:

Orlando Fla, May 17-22

		Prevention of Spread of HCV
		Sexual Activity as a Risk Factor for Hepatitis C Infection
		Maternal-Infant Transmission
		Introduction to Therapy of Hepatitis C
		Optimal Therapy of Hepatitis C
		Retreatment of Patients With Chronic Hepatitis C
		Treatment for Hepatitis C: A Systematic Review
		Utilization of Virologic Testing in the Treatment of Chronic Hepatitis C
		The Role of Liver Biopsy in Therapy of Chronic Hepatitis C
		Children with Hepatitis C
		Patients with Normal ALT Levels
		Patients with Advanced Disease
		Therapy of Acute Hepatitis C
		Hepatitis C and HIV
		Injection Drug Use and Hepatitis C
		Alcohol and Hepatitis C
		Special Populations
		Side Effects of Therapy and Management
		Future Therapy of Hepatitis C
		Pegylated Interferon Alfa-2b plus Ribavirin in Patients with Chronic Hepatitis C: A Trial in Prior Nonresponders to Interferon Monotherapy or Combination Therapy and in Combination Therapy Relapsers
		Pegylated Interferon Alfa 2b (PEG-IFN) and Ribavirin for Hepatitis C Patients who Were Nonresponders to Previous Therapy
		Prediction of Early Virologic Response to Treatment with 40KD Pegylated (PEG)-Interferon (IFN) Alfa2a/Ribavirin in Patients with Chronic Hepatitis C (Genotype 1)
		Interferon Alfa-2b and Ribavirin for Patients with Chronic Hepatitis C and Normal ALT: Final Results
		Amantadine Therapy for Chronic Hepatitis C: A Randomized Double-Blind Placebo Controlled Trial
		Pegylated (40 kDa, Branched) Interferon Alfa-2a (PEG-IFN) and Ribavirin (RIBA) in IFN-naive Patients with Hepatitis C and Advanced Fibrosis/Cirrhosis: Interim Results of a Randomized, Controlled Trial
		Pegylated Interferon Alfa-2b (PEG-IFN) Plus Ribavirin Versus PEG-IFN for Treatment of HIV/HCV Co-infected Patients (pts): An Open, Multicenter, Randomized Trial
		Pegylated Interferon alfa-2b and Ribavirin for the Treatment of Chronic Hepatitis C Infection in African Americans and Non-Hispanic Whites. A Preliminary Report.
		Sampling Variability on Percutaneous Liver Biopsy in Patients with Chronic Hepatitis C Virus Infection.
		The Impact of Intervening Substance Abuse on Hepatitis C Treatment Outcomes in Recovering Injection Drug Users: An Interim Analysis
		Alpha Feto-Protein Levels in Hepatitis C Subjects Treated with Combination Therapy: Abnormal Levels Decline with Therapy
		Does Normal ALT Exclude Severe Hepatic Fibrosis in Patients with Chronic Hepatitis C?
		Hepatitis C Treatments in Current Clinical Development